Scientists test common Antibiotic's impact on experimental cancer treatment
NCT ID NCT00750841
Summary
This early-phase study aims to understand how taking the antibiotic rifampicin affects how the body processes the experimental cancer drug cediranib. It involves 64 patients with advanced solid tumors that haven't responded to standard treatments. The main goal is to measure drug levels in the blood to see if the antibiotic changes them, while also checking for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Dundee, DD1 9SY, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE1 9RT, United Kingdom
Conditions
Explore the condition pages connected to this study.